Nplate® (romiplostim) Non-oncology

Nplate (romiplostim) is covered only for the FDA‑approved non‑oncology indication—treatment of immune thrombocytopenia (ITP) after inadequate response to corticosteroids, IVIG, or splenectomy—and is not covered for oncology uses. Coverage requires hematology prescribing/consultation, documented platelet count <30 x10^9/L (or <50 x10^9/L with increased bleeding risk), prior therapy or splenectomy, initial approval for 3 months (reauthorization 12 months) with documented clinical benefit and ongoing bleeding risk, and dosing starting at 1 mcg/kg weekly not to exceed 10 mcg/kg.

"Immune Thrombocytopenia with platelet count <50 x 10^9 / L (<50,000 / µL) and the patient is at an increased risk of bleeding."

Sign up to see full coverage criteria, indications, and limitations.